Your browser doesn't support javascript.
loading
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
Hong, David; Rasco, Drew; Veeder, Michael; Luke, Jason J; Chandler, Jason; Balmanoukian, Ani; George, Thomas J; Munster, Pamela; Berlin, Jordan D; Gutierrez, Martin; Mita, Alain; Wakelee, Heather; Samakoglu, Selda; Guan, Shanhong; Dimery, Isaiah; Graef, Thorsten; Borazanci, Erkut.
Afiliação
  • Hong D; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA, dshong@mdanderson.org.
  • Rasco D; Department of Clinical Research, South Texas Accelerated Research Therapeutics, Houston, Texas, USA.
  • Veeder M; Department of Oncology, Illinois Cancer Care, Peoria, Illinois, USA.
  • Luke JJ; Department of Medicine, University of Chicago, Chicago, Illinois, USA.
  • Chandler J; Department of Oncology and Hematology, West Cancer Center, Memphis, Tennessee, USA.
  • Balmanoukian A; Department of Oncology, The Angeles Clinic and Research Institute, Los Angeles, California, USA.
  • George TJ; Department of Medicine, University of Florida Health Cancer Center, Gainesville, Florida, USA.
  • Munster P; Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • Berlin JD; Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
  • Gutierrez M; Department of Hematology and Oncology, Hackensack University Medical Center, Hackensack, New Jersey, USA.
  • Mita A; Department of Experimental Therapeutics, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Wakelee H; Division of Oncology, Department of Medicine, Stanford University, Stanford, California, USA.
  • Samakoglu S; Department of Clinical Science, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, California, USA.
  • Guan S; Department of Biostatistics, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, California, USA.
  • Dimery I; Department of Clinical Science, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, California, USA.
  • Graef T; Department of Clinical Science, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, California, USA.
  • Borazanci E; Department of Clinical Translational Research, HonorHealth/TGen, Scottsdale, Arizona, USA.
Oncology ; 97(2): 102-111, 2019.
Article em En | MEDLINE | ID: mdl-31230047
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Inibidores de Proteínas Quinases / Antígeno B7-H1 / Tirosina Quinase da Agamaglobulinemia / Anticorpos Monoclonais / Neoplasias / Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Oncology Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Inibidores de Proteínas Quinases / Antígeno B7-H1 / Tirosina Quinase da Agamaglobulinemia / Anticorpos Monoclonais / Neoplasias / Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Oncology Ano de publicação: 2019 Tipo de documento: Article